Yüceer Ramazan Oğuz, Başpınar Şirin
Medical Pathology, Batman Training and Research Hospital, Batman, TUR.
Medical Pathology, Süleyman Demirel University Faculty of Medicine, Isparta, TUR.
Cureus. 2024 Feb 29;16(2):e55297. doi: 10.7759/cureus.55297. eCollection 2024 Feb.
In our study, it is aimed to investigate the relationship between Ki67 and phospho-histone H3 (pHH3) expressions in bladder urothelial carcinomas, with clinicopathological parameters and survival, which have prognostic value.
The study included 44 cases of high-grade urothelial carcinoma (HGUC), 37 cases of low-grade urothelial carcinoma (LGUC), and 11 nontumoral bladder cases. Ki67 and pHH3 were applied to the paraffin blocks of the tissues of 81 urothelial carcinoma and 11 nontumoral bladder cases by immunohistochemical method. Percentages of Ki67 and pHH3 expressions were evaluated by digital imaging analysis method. Expression percentages were compared with various clinicopathological parameters, and the relationship between them was evaluated.
Ki67 was expressed in 28% of urothelial carcinoma cases and 1% of nontumoral cases. pHH3 was expressed in 10.32% of urothelial carcinoma cases and 0.16% of nontumoral cases. In our study, we found significantly higher Ki67 and pHH3 expressions in urothelial carcinoma compared to nontumoral cases. There was a statistically significant relationship (p < 0.05) and a positive correlation between Ki67 expression and lymphovascular invasion, pT stage, and histological grade. A statistically significant relationship (p < 0.05) and a positive correlation were found between pHH3 expression and lymphovascular invasion, pT stage, recurrence, and histological grade. In addition, a statistically significant relationship was found between Ki67 and pHH3 expressions. In our study, survival was found to be low in high-grade urothelial carcinoma cases with lymphovascular invasion, advanced age (65 years and older), and high Ki67 and pHH3 expression rates.
According to our findings, high Ki67 and pHH3 expressions were found to be associated with poor prognostic parameters such as advanced pathologic stage, high histologic grade, and low survival. Our findings suggest that Ki67 and pHH3 may play a role in the differentiation, progression, and aggressive behavior of urothelial carcinoma. However, further studies are needed to confirm our findings and determine the role of these markers in urothelial carcinoma.
在我们的研究中，旨在探讨膀胱尿路上皮癌中Ki67与磷酸化组蛋白H3（pHH3）表达之间的关系，以及它们与具有预后价值的临床病理参数和生存率之间的关系。
该研究纳入了44例高级别尿路上皮癌（HGUC）、37例低级别尿路上皮癌（LGUC）和11例非肿瘤性膀胱病例。通过免疫组织化学方法将Ki67和pHH3应用于81例尿路上皮癌和11例非肿瘤性膀胱病例的组织石蜡块。采用数字成像分析方法评估Ki67和pHH3表达的百分比。将表达百分比与各种临床病理参数进行比较，并评估它们之间的关系。
Ki67在28%的尿路上皮癌病例和1%的非肿瘤病例中表达。pHH3在10.32%的尿路上皮癌病例和0.16%的非肿瘤病例中表达。在我们的研究中，我们发现与非肿瘤病例相比，尿路上皮癌中Ki67和pHH3的表达明显更高。Ki67表达与淋巴管浸润、pT分期和组织学分级之间存在统计学显著关系（p < 0.05）和正相关。pHH3表达与淋巴管浸润、pT分期、复发和组织学分级之间存在统计学显著关系（p < 0.05）和正相关。此外，Ki67和pHH3表达之间存在统计学显著关系。在我们的研究中，发现伴有淋巴管浸润、高龄（65岁及以上）以及高Ki67和pHH3表达率的高级别尿路上皮癌病例生存率较低。
根据我们的研究结果，发现高Ki67和pHH3表达与病理分期晚、组织学分级高和生存率低等不良预后参数相关。我们的研究结果表明，Ki67和pHH3可能在尿路上皮癌的分化、进展和侵袭性行为中发挥作用。然而，需要进一步的研究来证实我们的发现，并确定这些标志物在尿路上皮癌中的作用。
